Aging, immune senescence, and immunotherapy: A comprehensive review

Elias, Rawad; Hartshorn, Kevan L.; Rahma, Osama E.; Lin, Nina; Snyder‐Cappione, Jennifer

doi:10.1053/j.seminoncol.2018.08.006

Cited by 68 publications

(57 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunosuppressive agents are effective in most cases, especially if treatment is initiated promptly; however, severe and sometimes fatal toxicities have been reported . It is not clear, based on current data, if the toxicity profile of ICIs is similar across age groups, with some reports suggesting a higher rate of AEs in older adults and others showing comparable safety across age groups . Although numerical age, based on current limited data, does not seem to have a significant effect on the clinical profile of ICIs, it is still not clear if frailty has any impact on the efficacy or toxicity of these agents.…”

Section: Lung Cancermentioning

confidence: 89%

“…Although numerical age, based on current limited data, does not seem to have a significant effect on the clinical profile of ICIs, it is still not clear if frailty has any impact on the efficacy or toxicity of these agents. Changes in the immune system are observed in frail older adults; however, they are not well characterized and their significance, especially in the setting of immunotherapy, is not clear …”

Section: Lung Cancermentioning

confidence: 99%

“…74,75 It is not clear, based on current data, if the toxicity profile of ICIs is similar across age groups, with some reports suggesting a higher rate of AEs in older adults and others showing comparable safety across age groups. 76 Although numerical age, based on current limited data, does not seem to have a significant effect on the clinical profile of ICIs, it is still not clear if frailty has any impact on the efficacy or toxicity of these agents. Changes in the immune system are observed in frail older adults; however, they are not well characterized and their significance, especially in the setting of immunotherapy, is not clear.…”

Section: Casementioning

confidence: 99%

“…Changes in the immune system are observed in frail older adults; however, they are not well characterized and their significance, especially in the setting of immunotherapy, is not clear. 76…”

Section: Casementioning

confidence: 99%

See 3 more Smart Citations

Expanding Therapeutic Options for Older Adults: Case‐Based Updates in Breast and Lung Cancer

Magnuson

Elias

Koll

2019

J American Geriatrics Society

Self Cite

View full text Add to dashboard Cite

Oncology care has become increasingly complex, with a dramatic increase in the number of available therapy options. Many newly developed medications have novel mechanisms of action and include targeted therapies and immunotherapy options. These agents typically have unique side effects that differ from more traditional cytotoxic chemotherapy regimens. Older adults represent the majority of patients with cancer and it is important for geriatricians and primary care providers for older adults to have a general understanding of newer agents and novel therapies, in order to aid in decision‐making and supportive care strategies during oncology treatment. This review provides a case‐based approach to discussing emerging therapeutic treatment options, including targeted therapies and immune‐based therapies, in two common malignancies affecting older adults. Incorporation of available evidence of specific novel therapies in older adult populations is discussed. J Am Geriatr Soc 67:1012–1019, 2019.

show abstract

Section: Lung Cancermentioning

confidence: 89%

Section: Lung Cancermentioning

confidence: 99%

Section: Casementioning

confidence: 99%

Section: Casementioning

confidence: 99%

See 2 more Smart Citations

Expanding Therapeutic Options for Older Adults: Case‐Based Updates in Breast and Lung Cancer

Magnuson

Elias

Koll

2019

J American Geriatrics Society

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, as host immunity is also significant to eliminate cancer cells, its clinical impact on cancer immunotherapy is still largely unknown. Immunosenescence, which refers to the decline of immune system with aging, may contribute to reduced tumor cell clearance efficiency in body, leading to increased cancer incidence in the elderly [4].…”

mentioning

confidence: 99%

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age

et al. 2020

Biomark Res

View full text Add to dashboard Cite

High tumor mutation burden (TMB), which is associated with increased tumor immunogenicity, has been identified to predict improved response to immune checkpoint inhibitors (ICIs) therapy in non-small cell lung cancer (NSCLC). As host immunity is also significant to eliminate cancer cells, however, its clinical impact on cancer immunotherapy is still largely unknown. Here we explored the influence of age, which is an important characteristic to evaluate immune response of patients, on TMB-based predictive system for ICIs therapy in NSCLC. Our results showed that high TMB was capable of predicting better durable clinical benefit (DCB) in age low group, while it was insignificant in age high group. Besides, the predictive power of TMB for progression-free survival (PFS) and overall survival (OS) was better in age low group than in age high group. Our study illustrated that the predictive value of TMB for ICIs therapy was better in young patients than in elderly patients in NSCLC.

show abstract

A risk model of 10 aging‐related genes for predicting survival and immune response in triple‐negative breast cancer

et al. 2022

View full text Add to dashboard Cite

Accumulated studies showed that the clinical significance of aging on the development and malignancy of tumors, while the relationship between aging and the prognosis, immune response in triple‐negative breast cancer (TNBC) has not been well clarified. Here, we constructed a risk model of 10 prognostic aging‐related genes (ARGs) from METABRIC database. Then, TNBC patients were classified into high‐ and low‐risk groups, the survival diversity, immune response, genomic function, and tumor mutation burden (TMB) between different risk groups were explored in METABRIC, TCGA, and GSE58812 cohorts. Results showed that patients in the high‐risk group had poorer survival outcomes compared to their counterparts (all p < 0.05), and the nomogram we established showed reliable prediction ability for survival in TNBC patients. Besides, TNBC patients with high‐risk scores had a lower expression of immune checkpoint markers and a lower fraction of activated immune cells. Furthermore, GSEA showed that Notch signaling pathway was significantly enriched in the high‐risk group. Thus, a risk model based on the aging‐related genes was developed and validated in this study, which may serve as a potential biomarker for prognosis and personalized treatment in TNBCs.

show abstract

Aging, immune senescence, and immunotherapy: A comprehensive review

Cited by 68 publications

References 159 publications

Expanding Therapeutic Options for Older Adults: Case‐Based Updates in Breast and Lung Cancer

Expanding Therapeutic Options for Older Adults: Case‐Based Updates in Breast and Lung Cancer

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age

A risk model of 10 aging‐related genes for predicting survival and immune response in triple‐negative breast cancer

Contact Info

Product

Resources

About

Aging, immune senescence, and immunotherapy: A comprehensive review

Cited by 68 publications

References 159 publications

Expanding Therapeutic Options for Older Adults: Case‐Based Updates in Breast and Lung Cancer

Expanding Therapeutic Options for Older Adults: Case‐Based Updates in Breast and Lung Cancer

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age

A risk model of 10 aging‐related genes for predicting survival and immune response in triple‐negative breast cancer

Contact Info

Product

Resources

About

Aging, immune senescence, and immunotherapy: A comprehensive review